Does WellCare Cover Tirzepatide? Mounjaro, Zepbound, and Prior Authorization

WellCare may cover tirzepatide, but the answer depends on which brand you’re prescribed, why you’re taking it, and which WellCare plan you have. Mounjaro, the tirzepatide brand approved for Type 2 diabetes, appears on some WellCare formularies with prior authorization. Zepbound, the tirzepatide brand approved for weight management, is not covered when prescribed solely for weight loss, though it may be covered when prescribed for moderate-to-severe obstructive sleep apnea in adults with obesity. Medicare Part D is barred by law from paying for drugs prescribed only for weight loss, so that limit applies across every WellCare plan.1WellCare. Does Medicare Cover Weight Loss Drugs

Mounjaro for Type 2 Diabetes

WellCare lists Mounjaro as a formulary option on at least some plans for members with Type 2 diabetes. In its 2026 formulary changes effective January 1, 2026, WellCare named Mounjaro as a “Formulary Alternative” for Bydureon BCise, which was removed from the formulary. The listing carries a prior authorization requirement.2WellCare. WellCare 2026 Formulary Changes

Mounjaro is not on every WellCare drug list. The 2026 Wellcare Value Script PDP formulary document did not include a Mounjaro listing and directed members who cannot find their drug to contact Member Services or request a formulary exception.3Formulary Navigator. Wellcare Value Script PDP Comprehensive Formulary 2026 Medicare Advantage plans may also carry Mounjaro for diabetes, but the specifics vary by plan and state.1WellCare. Does Medicare Cover Weight Loss Drugs The only reliable way to confirm is to search your plan’s drug list online or call the number on your member ID card.

What Prior Authorization Requires

Where Mounjaro is covered, WellCare requires prior authorization before the pharmacy will fill the prescription, and the plan may apply step therapy or quantity limits.1WellCare. Does Medicare Cover Weight Loss Drugs The prescribing provider submits clinical documentation to show the drug is medically necessary for an FDA-approved use. Available information about WellCare’s criteria indicates that generally includes:

  • A confirmed diagnosis of Type 2 diabetes.
  • A documented hemoglobin A1c between 7% and 10% within the prior three months.
  • Evidence of inadequate response to prior treatments such as metformin or combination therapy.
  • A prescription from an endocrinologist or provider specializing in diabetes management, with a comprehensive diabetes management plan.

Continued coverage typically requires follow-up documentation every three to six months showing clinical benefit, such as a reduction in A1c from baseline.4getCurex. Does WellCare Cover Tirzepatide (Mounjaro)

Zepbound for Obstructive Sleep Apnea

Zepbound is not covered by WellCare when the prescription is for weight loss alone. That restriction comes from Medicare Part D, not from WellCare.1WellCare. Does Medicare Cover Weight Loss Drugs

There is one exception. Zepbound may be covered when prescribed to treat moderate-to-severe obstructive sleep apnea in adults with obesity, because that is a separate FDA-approved indication. Coverage still depends on whether your specific WellCare plan includes Zepbound on its formulary, and prior authorization is likely required. The provider needs to submit the sleep apnea diagnosis, sleep study results, BMI, and records of any previous treatments.1WellCare. Does Medicare Cover Weight Loss Drugs Medicare Part D plans generally require that the diagnosis be confirmed through an in-lab sleep study or home sleep apnea test, and some plans expect CPAP therapy to have been tried first.5American Sleep Apnea Association. Does Medicare Cover Zepbound for Sleep Apnea

What You’ll Pay When It’s Covered

WellCare does not publish a single copay for tirzepatide because the cost depends on the plan, the pharmacy, and the formulary tier. Expensive brand-name drugs often sit on specialty tiers that use coinsurance rather than flat copays. Under WellCare’s general Part D cost structure for 2026, members typically pay 25% coinsurance for covered drugs during the initial coverage phase until they reach the annual $2,100 out-of-pocket maximum. Some plans carry a deductible of up to $615; others have a lower or $0 deductible. Once the $2,100 cap is hit, covered drugs cost $0 for the rest of the year.1WellCare. Does Medicare Cover Weight Loss Drugs

For context, one WellCare PDP formulary document shows Tier 5 (specialty) drugs at 25% coinsurance and Tier 4 (non-preferred) drugs at roughly 34% to 50% depending on the pharmacy.6Formulary Navigator. Wellcare Enhanced PDP Comprehensive Formulary Without knowing which tier Mounjaro lands on for a given plan, a precise dollar figure isn’t possible.

The $50 GLP-1 Bridge for Weight Loss

If you want tirzepatide specifically for weight management, there is now a federal pathway outside the regular Part D benefit. The Medicare GLP-1 Bridge is a CMS demonstration project running from July 1, 2026, through December 31, 2027, providing eligible Medicare beneficiaries access to Zepbound and Wegovy for weight management at a fixed $50 monthly copay.7CMS. CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries

WellCare does not administer the Bridge. Humana serves as the central processor for prior authorizations, claims, and pharmacy payments, and WellCare members do not need their plan to opt in because the Bridge runs independently of Part D plan sponsors. When a provider submits a prior authorization for a Bridge-covered drug, CMS has encouraged Part D plans like WellCare to direct the provider to the central processor rather than process the request themselves.8CMS. Medicare GLP-1 Bridge

To qualify, you must be 18 or older, have Medicare Part D coverage (through a standalone PDP or a Medicare Advantage plan), and meet one of these clinical thresholds:

  • BMI of 35 or higher.
  • BMI of 30 or higher with at least one qualifying condition such as heart failure, uncontrolled hypertension, or chronic kidney disease (stage 3a or higher).
  • BMI of 27 or higher with pre-diabetes, a history of heart attack or stroke, or symptomatic peripheral artery disease.

You are not eligible for the Bridge if you already receive a GLP-1 drug through your standard Part D benefit, or if you have Type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. Those conditions have their own route through the regular Part D formulary process.9Medicare.gov. Weight Loss Drugs

One caveat worth planning around: the $50 Bridge copay does not count toward your Part D deductible or out-of-pocket maximum. Extra Help and the Medicare Prescription Payment Plan cannot be applied to Bridge copays either.10Medicare Rights Center. GLP-1 Weight Loss Drug Demonstration Begins July 2026

If Your Plan Says No

If your plan doesn’t list tirzepatide, or if a prior authorization request is denied, you can request a formulary exception by submitting a coverage determination request online, by mail, by fax, or by phone. The prescribing provider must include a statement explaining why the drug is medically necessary and why alternatives on the formulary would be less effective or cause adverse effects. WellCare must respond within 72 hours of receiving the provider’s statement for a standard request, or within 24 hours for an expedited request when a delay could seriously harm your health.11WellCare. Coverage Information Exceptions

If the exception is denied, you have 65 days from the denial notice to appeal. The appeal should include the drug name, strength, dosage, the reason for the appeal, and supporting medical records from the prescriber. Expedited appeals, decided within 72 hours, are available when the standard seven-day timeline could seriously harm your health.12WellCare. Drug Coverage Determination Appeal

Paying Out of Pocket

If no coverage path works, tirzepatide is available at retail. Eli Lilly sells Zepbound through its LillyDirect pharmacy at prices starting at $299 per month for the lowest dose and up to $449 per month for higher doses, with a refill required within 45 days to maintain the capped price. Lilly’s savings card programs are not available to anyone with government-sponsored insurance, including Medicare and Medicaid beneficiaries.13Eli Lilly. Zepbound Coverage and Savings

Under a November 2025 agreement between Eli Lilly and the federal government, Medicare beneficiaries were expected to pay no more than $50 per month for Zepbound beginning as early as April 2026, which aligns with the Bridge pricing. Lilly also added Mounjaro to the LillyDirect self-pay channel at prices 50–60% below current list prices, though specific amounts were not provided in the announcement.14Eli Lilly. Lilly and US Government Agree to Expand Access to Obesity Medicines